Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
12. April 2023 07:30 ET
|
Adaptive Biotechnologies
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
06. April 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
27. Februar 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
14. Februar 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
23. Januar 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
27. Dezember 2022 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
10. Dezember 2022 10:00 ET
|
Adaptive Biotechnologies
Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-makingMore than 30 clonoSEQ-related abstracts to be presented at the...
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
05. Dezember 2022 07:30 ET
|
Adaptive Biotechnologies
SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit...
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
01. Dezember 2022 07:30 ET
|
Adaptive Biotechnologies
clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens, and timepointsAdaptive now accepts blood samples from DLBCL patients in Streck®...
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
21. November 2022 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...